Skip to main content

Table 1 Baseline characteristics

From: Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study)

 

Saroglitazar 2 mg (N = 380)

Saroglitazar 4 mg (N = 386)

Pioglitazone 30 mg (N = 389)

Subjects characteristics

 Age (years), m ± SD

51.90 ± 10.38

51.34 ± 10.06

51.84 ± 9.76

 Female, n (%)

164 (43.16%)

143 (37.05%)

167 (42.93%)

 Male, n (%)

216 (56.84%)

243 (62.95%)

222 (57.07%)

 Weight (kg), m ± SD

70.27 ± 11.84

69.09 ± 11.46

69.49 ± 11.59

 BMI (kg/m2), m ± SD

26.48 ± 4.03

25.94 ± 3.87

26.33 ± 4.07

Glycemic parametersa, m ± SD

 HbA1C (%)

9.76 ± 1.59

9.72 ± 1.58

9.49 ± 1.54

 FPG (mg/dL)

166.08 ± 46.14

165.41 ± 51.39

165.08 ± 51.45

 PPG (mg/dL)

275.90 ± 84.74

277.42 ± 90.57

277.35 ± 88.05

Lipid parametersa, m ± SD

 TG (mg/dL)

163.87 ± 91.49

172.52 ± 123.67

166.20 ± 89.93

 LDL-C (mg/dL)

117.11 ± 36.92

112.93 ± 34.89

116.77 ± 32.31

 VLDL-C (mg/dL)

32.77 ± 18.30

34.50 ± 24.73

33.24 ± 17.99

 HDL-C (mg/dL)

42.39 ± 10.58

41.50 ± 10.47

42.64 ± 12.72

 TC (mg/dL)

176.98 ± 42.67

174.03 ± 39.32

176.42 ± 37.83

 Non HDL-C (mg/dL)

134.62 ± 41.06

132.54 ± 39.12

133.78 ± 35.39

Apolipoproteinsa, m ± SD

 Apo A1 (mg/dL)

128.72 ± 23.87

124.89 ± 23.05

127.15 ± 22.80

 Apo B (mg/dL)

100.64 ± 29.77

98.79 ± 26.06

100.60 ± 23.07

  1. Apo apolipoprotein A1, Apo B apolipoprotein B, BMI body mass index, dL decilitre, FPG fasting plasma glucose, HbA1c glycosylated hemoglobin, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, mg milligram, m mean, n number, N number of patients in each treatment group, PPG postprandial plasma glucose, SD standard deviation, TC total cholesterol, TG triglyceride, VLDL-C very low-density lipoprotein cholesterol
  2. aRepresents baseline value for per-protocol population